Researchers analyzed the unit prices of drugs classified as “high-spend” medications — based on volume, price or both — and found large price increases in this category.
Here are 10 “high-spend” drugs with the most significant price increases. The figures represent total spending by group purchasing organizations for more than 1,400 hospitals, according to the American Hospital Association.
Drug: 2013 spending — 2014 spending — 2015 spending
- Calcitonin-salmon: $4,932,748 — $12,529, 284 — $73,082,412
- Ephedrine sufate: $7,533,234 — $10,528,689 — $34,552,474
- Glycopyrrolate: $4,932,748 — $66,606,577 — $73,082,412
- Hydralazine: $6,951,150 — $7,725,372 — $17,568,936
- Isoproterenol: $5,602,447 —$23,066,826 — $86,541,461
- Neostigmine methysulfate: $56,818 — $4,311,153 — $78,814,217
- Nitroprusside: $9,802,140 —$48,278,606 — $94,966,434
- Phytonadione: $12,731,141 — $20,809,335 — $35,609,824
- Pyrimethamine: $595,748 — $801,690 — $812,109
- Sodium benzoate: $4,857,185 — $3,559,993 — $12,651,343
More articles on supply chain:
Roche subsidiary earns priority review status for drug Lucentis
St. Jude Medical issues warning on heart device after 2 patient deaths
Cost is king: 5 thoughts on the hospital supply chain from an expert who’s seen both sides of the business
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
